Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]RP-115 PET Imaging in Alzheimer's and Frontotemporal Dementia
NCT05374278Phase 2Recruiting
- Start
- Nov 2021
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of [18F]RP-115 in Alzheimer's disease (AD) and frontotemporal dementia (FTD) (4 cohorts). Primary endpoints: Safety of Administered dose at 1 year, Dosimetry of [18F]RP-115 at 1 year and 1 more. Started Nov 2021; status: recruiting.
02
Drugs
[18F]RP-115
03
Conditions
Alzheimer's disease (AD)frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT05374278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05374278.